Lupin Launches Anti Influenza Drug Oseltamivir Phosphate in USA | CORPORATE ETHOS

Lupin Launches Anti Influenza Drug Oseltamivir Phosphate in USA

By: | February 12, 2018
lupin

Feb 12: Mumbai-based pharma firm Lupin Ltd on Monday announced the launch of its Oseltamivir Phosphate Capsules, USP having received an approval from the United States Food and Drug Administration (USFDA) earlier.

“Lupin’s Oseltamivir Phosphate Capsules, USP , 30 mg (base), 45 mg (base), and 75 mg (base) are the generic equivalent of Hoffman-La Roche, Inc.’s Tamiflu Capsules, 30 mg, 45 mg, and 75 mg. Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base) are indicated for the treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours, and prophylaxis of influenza A and B in patients 1 year and older,” the company said.

According to IQVIA MAT December 2017 data, Oseltamivir Phosphate Capsules, USP had annual sales of approximately $518 million in the US.

Lupin shares were trading at Rs 840.95, up 2.44% from the previous closing of Rs 820.90, on BSE at 1.47 pm today.